TECHNOLOGY SUMMARY
2DG is a reversible inhibitor of glycolysis in development for treatment of status epilepticus and for prevention of delayed consequences of traumatic brain injury (TBI) including posttraumatic epilepsy (PTE) and posttraumatic stress disorder (PTSD). 2DG has acute anticonvulsant actions in multiple in vivo and in vitro preclinical seizure models.
AREA/MATURITY/AWARDS
Primary Application Area: Healthcare & Medical Devices
Technology Development Status: Proven Manufacturability
Technology Readiness Level: TRL 5
Vetted Programs/Awards: NIH NCATS BrIDGs program
GOVT/EXTERNAL FUNDING SOURCES
External Funding to Date: WARF is investing more than 130K in advancing this technology
Epilepsy Foundation has supported this technology with 100K grant